Tocilizumab fails to improve long-term outcomes in acute myocardial infarction despite reducing inflammation

Acute myocardial infarction (AMI), characterized by myocardial necrosis due to ischemia, remains a leading cause of global mortality and morbidity. Despite advancements in revascularization strategies, ischemia-reperfusion injury and subsequent inflammatory responses significantly contribute to adverse outcomes. Interleukin-6 (IL-6), a key pro-inflammatory cytokine, plays a crucial role in driving this post-infarction inflammation, exacerbating myocardial damage and hindering repair. Current standard-of-care primarily focuses on restoring blood flow, but adjunctive therapies targeting specific inflammatory pathways like IL-6 are being explored to mitigate secondary injury and improve long-term cardiac function. Tocilizumab, an IL-6 receptor antagonist, has shown promise in modulating these inflammatory cascades.

This systematic review and meta-analysis adhered to the PRISMA Framework and was registered in PROSPERO, identifying relevant studies through comprehensive searches of PubMed, MEDLINE, Cochrane Library, and Google Scholar up to June 2025. The investigation focused on randomized and prospective trials evaluating IL-6 inhibition with tocilizumab in patients experiencing ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). Primary outcomes assessed included infarct size, inflammatory and cardiac biomarkers (c-reactive protein, troponin, NT-proßNP), major adverse cardiovascular events (MACE), and all-cause mortality. The analysis pooled data from three randomized controlled trials comprising a total of 344 patients.

Pooled analysis of 344 patients revealed that tocilizumab did not significantly reduce the risk of recurrent myocardial infarction compared to placebo (relative risk [RR] = 0.47, 95% confidence interval [CI] = 0.07-3.05; I2 = 44%; p = 0.43). Similarly, there was no significant difference in infection rates between the tocilizumab and placebo groups (RR = 0.85, 95% CI: 0.29-2.53; I2 = 0%; p = 0.77).

Mechanistic analysis demonstrated lower c-reactive protein (CRP) exposure, transient N-terminal pro-B-type natriuretic peptide (NT-proßNP) reductions, and attenuated troponin release in tocilizumab groups, indicating biological modulation of inflammatory and myocardial injury pathways during the acute phase. These acute benefits, while statistically significant for biomarkers, were most pronounced during hospitalization and diminished over time. Crucially, long-term outcomes, including ventricular remodeling, NT-proßNP levels at 6 months, and overall mortality, showed no significant group differences, suggesting a disconnect between acute inflammatory suppression and sustained clinical improvement.